SynthesisBreast cancer (Tokyo, Japan)2019

A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer.

John F R Robertson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.